L'OREAL Research and Innovation, 1, avenue Eugène Schueller, Aulnay-sous-Bois, 93600, France.
L'OREAL Research and Innovation, 188, rue Paul Hochart, Chevilly Larue, 94550, France.
Lasers Surg Med. 2021 Nov;53(9):1208-1219. doi: 10.1002/lsm.23398. Epub 2021 May 11.
Low-level light therapies using visible to infrared light are known to activate several cellular functions, such as adenosine triphosphate and nitric oxide synthesis. However, few clinical observations report its biological consequences for skin and scalp homeostasis. Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L.L.C., Virginia Beach, VA (US) could enhance hair regrowth activity of Minoxidil.
STUDY DESIGN/MATERIALS AND METHODS: We conducted a first experimental clinical study on 64 men with androgenetic alopecia using LLLT/GentleWaves®, 590-nm predominant wavelength 70 seconds, specifically pulsed once per day, for 3 days, and we performed a whole-genome analysis of treated scalp biopsies. In a second clinical study, including 135 alopecic volunteers, we evaluated the hair regrowth activity in response to the upgraded LLLT/GentleWaves® device and Minoxidil.
In the first clinical study, whole-genome analysis of treated scalp biopsies showed downregulation of scalp inflammatory biomarkers, such as AP1/FOSB messenger RNA (mRNA) and mir21, together with the disappearance of CD69 mRNA, specific to scalp-infiltrating T cells of about 50% of the studied volunteers prior to the LLLT/GentleWaves® treatment. In the second clinical study, we observed that LLLT/GentleWaves® was able to boost the hair regrowth activity of a Minoxidil 2% lotion to the extent of the highest concentration (5%) in terms of efficacy, number of responders, and perceived performance.
Altogether, these observations suggest the potential benefit of LLLT/GentleWaves® as a noninvasive adjunctive technology for skin and scalp conditions, where a mild perifollicular inflammation is involved. Lasers Surg. Med. 2021. Copyright © 2021 Wiley Periodicals LLC.
已知使用可见光到红外线的低水平光疗可激活多种细胞功能，如三磷酸腺苷和一氧化氮合成。然而，很少有临床观察报告其对皮肤和头皮稳态的生物学影响。由于头皮炎症被认为是体内参考毛发生长药物米诺地尔疗效的潜在生理障碍，并且由于毛囊周围炎症是雄激素性脱发中约 50%-70%毛囊单位的标志，我们决定研究低水平光疗/温和波®设备的抗炎活性是否可以增强米诺地尔的毛发生长活性。
研究设计/材料和方法：我们使用低水平光疗/温和波®设备（VA，美国弗吉尼亚海滩的 Light BioScience L.L.C. 公司分配给欧莱雅的产品）对 64 名患有雄激素性脱发的男性进行了首次实验性临床研究，该设备的主要波长为 590nm，每天一次，每次 70 秒，连续 3 天进行治疗，并对治疗后的头皮活检进行了全基因组分析。在第二项包括 135 名脱发志愿者的临床研究中，我们评估了升级后的低水平光疗/温和波®设备和米诺地尔对毛发生长的活性。
在第一项临床研究中，对治疗后的头皮活检进行的全基因组分析显示，头皮炎症生物标志物的表达下调，如 AP1/FOSB 信使 RNA（mRNA）和 mir21，同时约 50%的研究志愿者在接受低水平光疗/温和波®治疗前头皮浸润 T 细胞的 CD69 mRNA 消失。在第二项临床研究中，我们观察到低水平光疗/温和波®能够增强米诺地尔 2%洗剂的毛发生长活性，其疗效、应答者数量和感知性能与最高浓度（5%）相当。
总之，这些观察结果表明，低水平光疗/温和波®作为一种非侵入性的辅助技术，可能对涉及轻度毛囊周围炎症的皮肤和头皮状况有益。激光外科学杂志。2021. 版权所有©2021 威利父子公司。
